The European Commission has tasked the Avicenna Alliance with meeting a significant challenge – developing recommendations and plans for the implementation of the Avicenna Roadmap in policy.

The Policy Development Working Group aims to work towards the inclusion of Avicenna Alliance members’ interests in EU policies. Many EU policies, Directives and Regulations predate the existence of the very same in silico technologies they are designed to govern.

In order for the in silico market and research community to be enabled, current policies and legislations governing healthcare need to be updated. The creation of a framework for the validation of in silico models and the acceptance in the Regulatory system of data derived from modelling and simulation is a prerequisite for further investment in this field and the realization of its potential.

The key goals of this group are:

  • Identification of challenges for the in silico market and research community and the development of corresponding policy solutions;
  • Engagement with the European Parliament, Council and Commission on key dossiers and policy issues of importance to the Membership;
  • Communicate on the potential of in silico medicine for patients, healthcare professionals and industries.

Priorities in 2018

→ Demonstrate the importance of including in silico medicine in legislation on rare diseases and paediatrics in position papers;
→ Strengthen contacts with relevant bodies and institutions;
→ Contribute to the three upcoming Avicenna Alliance White Papers

Avicenna Alliance news

EU Commission steps up support for personalised medicine

In the past months, the EU has presented several initiatives that jointly have the potential to advance personalised medicine in Europe. Next...

find out more ›

In vivo, in vitro, in silico: Why computer modelling is the next evolution of the healthcare sector

International Conference on In Silico Medicine on 4 September

find out more ›

Cipla brings India perspectives on In Silico to Brussels

New Avicenna Member company Cipla shared some key insights on India’s perspective of In Silico medicine during a visit to Brussels in April....

find out more ›

Show all activites